The FDA awards conditional IDE approval to Kips Bay Medical, allowing the company to begin a clinical study of its eSVS mesh in coronary artery bypass graft surgery.
Kips Bay Medical (NSDQ:KIPS) won conditional FDA investigational device exemption approval for its eSVS mesh, allowing the company to begin a clinical study of the device in use during coronary artery bypass procedures.
The eSVS mesh provides support to keep vein grafts open during CABG procedures, and the FDA's blessing grants Kips Bay approval to include 4 U.S. study sites in its ongoing eMESH I clinical feasibility trial.
The eMESH studies began in Switzerland in August 2012 in hopes of reversing a previous FDA rejection of an eSVS IDE application.
The device is comprised of a flexible, knitted sleeve that fits around the outside of the vein in order to reduce vessel wall stress and mitigate the potential for vessel injury.
In September 2011 the FDA issued Kips Bay a non-approvable letter, asking for more information on the eSVS mesh before granting IDE approval for perform pivotal human trials.
That decision sent KIPS shares plummeting 34% to an new all-time low in a single day.
A federal jury in Texas clears Johnson & Johnson's DePuy Pinnacle hip implant in the 1st...
Edwards Lifesciences reports 3rd-quarter sales and earnings growth in excess of 20% and raises its...
A federal jury in Texas reportedly clears Johnson & Johnson's DePuy Pinnacle hip implant in the...
Federal auditors say the FDA needs to ramp up its cybersecurity efforts in order to deter hackers.